Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, United States.
Department of Pharmacology and Physiology, University of Rochester Medical Center, Rochester, NY, United States.
Prog Mol Biol Transl Sci. 2023;195:47-76. doi: 10.1016/bs.pmbts.2022.06.011. Epub 2022 Jul 13.
The endogenous ligands activating a large fraction of the G Protein Coupled Receptor (GPCR) family members have yet to be identified. These receptors are commonly labeled as orphans (oGPCRs), and because of the absence of available pharmacological tools they are currently understudied. Nonetheless, genome wide association studies, together with research using animal models identified many physiological functions regulated by oGPCRs. Similarly, mutations in some oGPCRs have been associated with rare genetic disorders or with an increased risk of developing pathologies. The once underestimated pharmacological potential of targeting oGPCRs is increasingly being exploited by the development of novel tools to understand their biology and by drug discovery endeavors aimed at identifying new modulators of their activity. Here, we summarize recent advancements in the field of oGPCRs and future directions.
激活大部分 G 蛋白偶联受体(GPCR)家族成员的内源性配体尚未被鉴定。这些受体通常被标记为孤儿受体(oGPCR),由于缺乏可用的药理学工具,它们目前的研究较少。尽管如此,全基因组关联研究以及使用动物模型的研究确定了许多由 oGPCR 调节的生理功能。同样,一些 oGPCR 的突变与罕见的遗传疾病或增加患病理的风险有关。曾经被低估的靶向 oGPCR 的药理学潜力,正随着开发用于了解其生物学的新型工具以及旨在鉴定其活性的新型调节剂的药物发现努力而得到越来越多的利用。在这里,我们总结了 oGPCR 领域的最新进展和未来方向。